Sequent Research Ltd, a wholly-owned subsidiary of Sequent Scientific Ltd, on September 11, 2015 opened its new good laboratory practices (GLP) compliant analytical services centre at Bangalore.
Built with a space of 10,000 square feet, the new Bangalore centre will enable company's access to a wider range of therapies including beta lactam and hormones.
"The Bengaluru analytical centre will expand our business horizon to include beta lactams, penicillin and other products. The demand for out-sourced research is growing and so is the need for reliable partner having a resilient framework for regulatory compliance, data integrity and ethics," said Kumud Sampath, CEO, Sequent Research.
Built with a space of 10,000 square feet, the new Bangalore centre will enable company's access to a wider range of therapies including beta lactam and hormones.
"The Bengaluru analytical centre will expand our business horizon to include beta lactams, penicillin and other products. The demand for out-sourced research is growing and so is the need for reliable partner having a resilient framework for regulatory compliance, data integrity and ethics," said Kumud Sampath, CEO, Sequent Research.